FindTrial
Sign In

XIENCE V EECSS

DEVICE2 trials

Sponsors

Abbott Medical Devices

Conditions

Coronary Artery DiseaseCoronary Artery StenosisCoronary DiseaseCoronary OcclusionCoronary RestenosisCoronary StenosisMyocardial IschemiaThrombosis (Stent Thrombosis)

Phase 4

XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
CompletedNCT01178268
Abbott Medical DevicesCoronary Artery Disease, Coronary Artery Stenosis, Coronary Disease +5
Start: 2010-08-31End: 2014-09-30Updated: 2016-08-24

Unknown Phase

A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)
CompletedNCT01923740
Abbott Medical DevicesCoronary Artery Disease, Coronary Artery Stenosis, Coronary Disease +1
Start: 2013-07-31End: 2019-03-07Updated: 2019-12-04

Related Papers

Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.
2025-01-018 citations
Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up: A Systematic Meta-analysis and Individual Patient Data Pooled Study.
2019-12-0168 citations
Three-Year Outcomes With the Absorb Bioresorbable Scaffold: Individual-Patient-Data Meta-Analysis From the ABSORB Randomized Trials.
2017-10-31119 citations
Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation: Analysis From the ABSORB Trials.
2017-10-31103 citations
1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
2016-01-27192 citations
Bioresorbable Vascular Scaffolds Versus Metallic Stents in Patients With Coronary Artery Disease: ABSORB China Trial.
2015-10-12178 citations